[
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for 2026. On January 28, Goldman Sachs reaffirmed its Neutral rating and $223 price target on AbbVie Inc. (NYSE:ABBV) ahead of its Q4 2025 earnings and 2026 guidance release. The firm expects healthy growth, projecting $67.1 billion in revenue, $21.3 billion from Skyrizi, […]",
    "url": "https://finnhub.io/api/news?id=6809fa3afa3098cb84e3c7b9cae95d951ab57e221e0fef40759e20d951766a14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769870153,
      "headline": "AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth",
      "id": 138315770,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for 2026. On January 28, Goldman Sachs reaffirmed its Neutral rating and $223 price target on AbbVie Inc. (NYSE:ABBV) ahead of its Q4 2025 earnings and 2026 guidance release. The firm expects healthy growth, projecting $67.1 billion in revenue, $21.3 billion from Skyrizi, […]",
      "url": "https://finnhub.io/api/news?id=6809fa3afa3098cb84e3c7b9cae95d951ab57e221e0fef40759e20d951766a14"
    }
  },
  {
    "ts": null,
    "headline": "Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Stocks to Buy for the Long Term. On January 27, Citi modestly cut its price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while leaving its Neutral rating unchanged. The adjustment was part of the firm’s broader Q4 review of the biopharma space. In its […]",
    "url": "https://finnhub.io/api/news?id=4b9735c3ac54bfdf754138cddcb6367e4f3144fa9028ce19dab6eeef9238fa0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769866270,
      "headline": "Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma",
      "id": 138315125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Stocks to Buy for the Long Term. On January 27, Citi modestly cut its price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while leaving its Neutral rating unchanged. The adjustment was part of the firm’s broader Q4 review of the biopharma space. In its […]",
      "url": "https://finnhub.io/api/news?id=4b9735c3ac54bfdf754138cddcb6367e4f3144fa9028ce19dab6eeef9238fa0c"
    }
  },
  {
    "ts": null,
    "headline": "Alphabet, Amazon, AMD Lead Earnings Wave; Jobs Data On Deck",
    "summary": "Wall Street Week Ahead: key earnings (Amazon, Alphabet), IPOs, dividends & economic data (NFP, PMI). Read here for more details.",
    "url": "https://finnhub.io/api/news?id=b3e63802df6853657bf27d4f27978ea3f127e889b8b510bff3c097715be8804b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769857200,
      "headline": "Alphabet, Amazon, AMD Lead Earnings Wave; Jobs Data On Deck",
      "id": 138315868,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Wall Street Week Ahead: key earnings (Amazon, Alphabet), IPOs, dividends & economic data (NFP, PMI). Read here for more details.",
      "url": "https://finnhub.io/api/news?id=b3e63802df6853657bf27d4f27978ea3f127e889b8b510bff3c097715be8804b"
    }
  },
  {
    "ts": null,
    "headline": "The DGI Core Portfolio: 2025 Year-End Review",
    "summary": "The DGI Core Portfolio: 2025 Year-End Review",
    "url": "https://finnhub.io/api/news?id=e38a9974b47fdf124d7722526fb6b47b07c252956c3234c64c67d2b489b06471",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769847300,
      "headline": "The DGI Core Portfolio: 2025 Year-End Review",
      "id": 138314876,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e38a9974b47fdf124d7722526fb6b47b07c252956c3234c64c67d2b489b06471"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s US$100b Pledge Raises Questions On Value, Margins And Debt",
    "summary": "AbbVie (NYSE:ABBV) has entered a voluntary agreement with the U.S. government to commit US$100b to U.S. research and development and capital investments over the next decade. The company is also launching a three year effort focused on lowering drug prices while expanding U.S. manufacturing and direct to patient care access. AbbVie is a large U.S. based pharmaceutical company with a portfolio that spans immunology, oncology and other therapeutic areas. The new commitment sits against a...",
    "url": "https://finnhub.io/api/news?id=e1e4465de0669164fd4f3c55301236b5c34f39764165206ed01124cc097a2163",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769836320,
      "headline": "AbbVie’s US$100b Pledge Raises Questions On Value, Margins And Debt",
      "id": 138313011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) has entered a voluntary agreement with the U.S. government to commit US$100b to U.S. research and development and capital investments over the next decade. The company is also launching a three year effort focused on lowering drug prices while expanding U.S. manufacturing and direct to patient care access. AbbVie is a large U.S. based pharmaceutical company with a portfolio that spans immunology, oncology and other therapeutic areas. The new commitment sits against a...",
      "url": "https://finnhub.io/api/news?id=e1e4465de0669164fd4f3c55301236b5c34f39764165206ed01124cc097a2163"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For February 2026",
    "summary": "Dividend Aristocrats lagged the S&P 500 in 2025 but started 2026 strong.",
    "url": "https://finnhub.io/api/news?id=800289596e0fb58f29b2e1070377b29fa7b3a4d167bb115d6581677c59423fb0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769833874,
      "headline": "Best Dividend Aristocrats For February 2026",
      "id": 138313889,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249594654/image_2249594654.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats lagged the S&P 500 in 2025 but started 2026 strong.",
      "url": "https://finnhub.io/api/news?id=800289596e0fb58f29b2e1070377b29fa7b3a4d167bb115d6581677c59423fb0"
    }
  }
]